In-vivo tracking of adoptively transferred natural killer-cells in rhesus macaques using 89Zirconium-oxine cell labeling and PET imaging

Purpose: Trials of adoptive natural killer (NK)-cell immunotherapy for hematological malignancies have thus far shown only marginal effects, despite the potent in-vitro anti-tumor activity of these cells. Homing of infused cells to tumor microenvironments is critical for efficacy but has not been well characterized. We established a novel method to track and quantify the distribution of adoptively transferred NK-cells using rhesus macaques (RMs) as a clinically relevant preclinical model. Experimental design: RM NK-cells were expanded ex-vivo for 14-21 days, labeled with 89Zr-oxine complex and assessed for phenotype, function and survival. Trafficking of 89Zr-labeled ex-vivo-expanded NK-cells infused into RMs was monitored and quantitated by serial positron emission tomography (PET)/computed tomography (CT) (n=3, 2.05 ± 0.72 MBq, 23.5 ± 2.0x106 NK-cells/kg) and compared to that of 89Zr-labeled non-expanded NK-cells, apoptotic NK-cells and hematopoietic stem and progenitor cells (HSPCs). Results: NK-cells retained sufficient levels of 89Zr for accurate in-vivo tracking for 7 days. 89Zr-labeling did not alter cellular phenotype, viability or function. PET/CT showed NK-cells initially localized in the lungs, followed by their migration to the liver, spleen and, at low levels, bone marrow (BM). One day following transfer, only 3.4% of infused NK-cells localized to the BM vs 22.1% of HSPCs. No clinical side effects were observed, and dosimetry analysis indicated low organ radio-exposures of 6.24 mSv/MBq (spleen) or lower. Conclusions: These data support translation of this technique to humans to track the distribution of adoptively infused cells and to develop novel techniques to improve immune cell homing to tumor microenvironments. Copyright ©2020, American Association for Cancer Research.

See More